Biotech News

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results

Pliant Therapeutics (PLRX)Pliant Therapeutics2026-03-11 20:05 ESTEarnings

PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumors PLN-101095 accelerated development plan underway with initiation of Phase 1b indication expansion trial SOUTH SAN FRANCISCO, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Pliant

Pliant Therapeutics

Integrin-Targeted Drug Discovery Pliant Therapeutics is a clinical-stage biotechnology company developing therapies that modulate integrin-mediated biological pathways. Its current development focus centers on oncology and targeted drug delivery. PLN-101095 PLN-101095 is an oral small molecule that selectively inhibits the αvβ8 and αvβ1...

Recent company news

PLRXPliant Therapeutics2026-08-18 12:30 EST

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors

PLRXPliant Therapeutics2026-08-11 20:05 EST

Stock data

Close: 1.10 USD
Market cap: 71.83M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results

Related news

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results